Retadose

Precision Retatrutide dosing via feedback loops. Log, track, and optimize your protocol with our free community-driven system at 🧬📈

[Retadose @HelloRetadose]

We are very close to launching our new Biometrics dashboard. Right now it supports the Google Ecosystem, wrist wearable like the Fitbit and Constant Glucose Meter like the Stelo.

If you are serious about tracking your Reta Journey, it's Retadose.

[Retadose @HelloRetadose]

Weight loss plateau ≠ drug failure. It's a data point that says 'time to reassess.' Your PK curve and check-in scores tell you exactly what to do next.

[Retadose @HelloRetadose]

The plateau is predictable. The quit is preventable. Track your levels, watch for adaptation signals, and adjust before frustration sets in.

[Retadose @HelloRetadose]

Why do people quit GLP-1s after 30 days of plateau? Because stagnation feels like failure. A dose adjustment plan prevents that emotional spiral.

[Retadose @HelloRetadose]

PK-guided dosing showed lower GI holds and higher adherence in observational data (~2,800 patient-weeks). Knowing your level changes behavior.

[Retadose @HelloRetadose]

Quick tip: Use a PK calculator + check-in data to know if you're underdosed vs metabolically adapted. The difference determines your next step.

[Retadose @HelloRetadose]

Real-world data: 46-65% of GLP-1 users discontinue at 12 months. Cost and side effects drive it — but plateau frustration tips the scale.

[Retadose @HelloRetadose]

'Maintenance dose' on retatrutide is NOT static. It's a moving target as receptor sensitivity down-regulates over time.

[Retadose @HelloRetadose]

How do you tell if you need a higher retatrutide dose vs your body just adapted? Check your PK level, review check-in scores, and look for the adaptation pattern.

[Retadose @HelloRetadose]

Myth: Pushing through nausea breaks a weight loss plateau.

Reality: Nausea at higher levels won't resolve without dose adjustment. More isn't always better.

[Retadose @HelloRetadose]

Signs of retatrutide adaptation:
• Appetite fully returned
• Zero GI symptoms
• Feels 'normal'
• Motivation flat

These are your signals to reassess dosing.

[Retadose @HelloRetadose]

Detect a retatrutide plateau by week 2. Adjust dose by week 3. Show visible progress resuming by week 4. The 30-day window is critical.

[Retadose @HelloRetadose]

For every 1% body weight lost on GLP-1s, the probability of quitting drops 3.3%. Early results keep people on track.

[Retadose @HelloRetadose]

Only 2% of people quit GLP-1s saying 'it didn't work.' But 10-15% are actual non-responders. Most plateau patients just need dose adjustment.

[Retadose @HelloRetadose]

Myth: A weight loss plateau means retatrutide stopped working.

Reality: It means your body adapted to that level. The drug works — your dose needs adjusting.

[Retadose @HelloRetadose]

Patients quit GLP-1s within 30 days of hitting a weight loss plateau. That's the psychological tipping point. Have a plan before you get there.

[Retadose @HelloRetadose]

Retatrutide vs tirzepatide isn't about which is 'better.' It's about which is right for YOUR situation — coverage, tolerance, dose flexibility, access.

[Retadose @HelloRetadose]

If you're choosing between these drugs, the biggest factor right now isn't efficacy — it's access. Tirzepatide has insurance; retatrutide doesn't.

[Retadose @HelloRetadose]

The retatrutide advantage: glucagon receptor activation increases resting energy expenditure. Your body burns more calories at rest — beyond appetite suppression.

[Retadose @HelloRetadose]

Tirzepatide (Mounjaro/Zepbound) is the current gold standard for approved GLP-1 weight loss drugs. Retatrutide is the most promising next-gen candidate.